A Clinicians Guide to Recommending Common Cholesterol-Lowering Dietary Supplements.

Area of Science:

• Cardiovascular Health
• Dietary Supplements
• Pharmacology

Background:

• The US dietary supplement market has grown significantly, offering numerous products marketed for cholesterol and cardiovascular benefits.
• The Food and Drug Administration faces challenges regulating this expanding market, leading to concerns about product quality and safety.
• Many supplements lack robust, well-designed randomized controlled trials (RCTs) to support their efficacy.

Purpose of the Study:

• To evaluate the current role and evidence base for common dietary supplements used for cardiovascular risk reduction.
• To identify specific supplements with potential benefits and highlight existing limitations, including quality control and inconsistent findings.
• To inform clinical practice regarding the appropriate use of dietary supplements in lipid management and overall cardiovascular health.

Main Methods:

• Review of recent randomized controlled trials (RCTs) and scientific literature on popular dietary supplements.
• Analysis of studies focusing on supplements like fish oil (eicosapentaenoic acid and docosahexaenoic acid), niacin, red yeast rice, garlic, phytosterols, psyllium, and berberine.
• Assessment of reported efficacy, safety concerns, quality control issues, and consistency of findings across studies.

Main Results:

• Prescription fish oil and niacin have shown mixed results and safety concerns, leading to limited recommendations in major cardiovascular guidelines.
• Red yeast rice demonstrates significant low-density lipoprotein cholesterol (LDL-C) reduction, but quality and study inconsistencies persist.
• Other supplements like garlic, phytosterols, psyllium, and berberine show modest LDL-C reductions and potential cardiometabolic benefits, though results remain inconsistent and quality concerns are noted.

Conclusions:

• Current evidence and quality concerns limit the role of most dietary supplements in routine clinical practice for cardiovascular risk management.
• While some supplements show promise, inconsistent findings and lack of regulatory assurance necessitate caution until product quality and label accuracy are guaranteed.
• Further research and improved regulatory oversight are needed to establish the safety and efficacy of dietary supplements for cardiovascular health.